A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

Conclusion At 15  mg/kg weekly, GSK3052230 was well tolerated in combination with pemetrexed/cisplatin and durable responses were observed. Importantly, AEs associated with small molecule inhibitors of FGFR were not observed, as predicted by the unique mechanism of action of this drug.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

Conditions:   Adenocarcinoma;   Adenocystic Carcinoma;   Anal Cancer;   Appendix Cancer;   Brain Tumor;   Glioblastoma;   Astrocytoma;   Bile Duct Cancer;   Cholangiocarcinoma;   Bladder Cancer;   Bone Cancer;   Synovial Sarcoma;   Chondrosarcoma;   Liposarcoma;   Sarcoma, Kaposi;   S arcoma,Soft Tissue;   Sarcoma;   Osteosarcoma;   CNS Cancer;   Brain Stem Neoplasms;   Breast Cancer;   Cervical Cancer;   Colorectal Cancer; &n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Despite banning all forms and uses of asbestos 20 years ago, Great Britain still has one of the world’s highest rates of mesothelioma cancer, according to the government’s Health and Safety Executive report. The July 2019 report revealed the number of annual deaths from mesothelioma in the country still is peaking and expected to begin a gradual decline in 2020. The report included 2,523 deaths in 2017 (the last year available) from mesothelioma, the rare and aggressive cancer caused by exposure to asbestos. It estimates as many as 2,637 others could die in 2019. Great Britain, which comprises the nations of E...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract The MERIT study was a single-arm, phase 2 clinical trial of nivolumab for the 2nd or 3rd line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan. PMID: 31315884 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractBackground.Multimodality therapy with preoperative radiation (RT) followed by extrapleural pneumonectomy (EP) for patients with operable malignant pleural mesothelioma (MPM) has demonstrated encouraging results. At relapse, there are few data on the tolerance and efficacy of systemic therapies after prior multimodality therapy.Materials and Methods.We conducted a retrospective analysis of patients with relapsed MPM after RT and EPP ± adjuvant chemotherapy to determine overall survival (OS; date of relapse to death) and the proportion of patients that received systemic therapy and associated response rate (RR...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer Source Type: research
Prophylactic radiotherapy — once offered routinely after invasive procedures for pleural mesothelioma — is an unnecessary treatment for patients, according to the most recent study from the United Kingdom. Results from a large, multicenter clinical trial have shown the treatment — used regularly for almost two decades — does little to prevent chest-wall metastasis that can occur with mesothelioma cancer. “This should be helpful for patients to know if their oncologist is offering something they don’t really need,” clinical oncologist Dr. Neil Bayman, associate medical director at t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Journal of Women's Health, Ahead of Print.
Source: Journal of Women - Category: OBGYN Authors: Source Type: research
The U.S. Justice Department is conducting a criminal investigation to determine if Johnson &Johnson misled the public about the possible presence of asbestos fibers and the resulting cancer risk in its talcum powder. According to Bloomberg News, a federal grand jury is examining whether company officials knew and denied their product once contained trace amounts of the toxic mineral. An ongoing regulatory investigation and thousands of lawsuits have coincided with the latest probe of the pharmaceutical giant. Johnson &Johnson is the world’s largest manufacturer of talc products, including its iconic Baby Powd...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
In conclusion, extensive genetic alterations exist in mesotheliomas associated with the signaling of apoptotic HM cells death. The comprehension of these pathways may contribute to enhancing survival via developing new effective therapeutic strategies.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Malignant Pleural Mesothelioma (MPM) is an aggressive tumor that arises from the mesothelial cells of the pleura [1]. It is well established that MPM is almost always caused by professional or non professional exposure to asbestos fibers, while the pathogenetic role of cofactors, such as SV40 viral infection, still remains controversial [2,3]. The average latency period between asbestos exposure and tumor presentation is 30-45 years, depending on duration or intensity of exposure and patient gender [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: An elevated rate of death from mesothelioma was observed in two radiation-exposed occupational groups with potential for asbestos exposure. The increased risk of death from asbestosis, combined with little evidence of a rising trend in mesothelioma mortality with increasing radiation exposure, suggests that the mesothelioma (and asbestosis) excess in these workers was due to asbestos exposure in shipyards and power plants and not to occupational low-dose radiation. PMID: 31290725 [PubMed - as supplied by publisher]
Source: International Journal of Radiation Biology - Category: Radiology Tags: Int J Radiat Biol Source Type: research
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Drugs & Pharmacology | Investigational New Drugs | Mesothelioma | Skin | Study | Toxicology | Vitamin A